EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adeno-Associated Virus-Based Gene Therapy for Lafora Disease in Epm2b-Deficient Mice

Luis Zafra-Puerta iD, Nerea Iglesias-Cabeza iD, Pascual Sanz iD, María Adelaida García-Gimeno iD, Gema Sánchez-Martín, Marina P Sánchez iD, José M Serratosa

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262411930 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Luis Zafra-Puerta und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Neurology, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, Sp…. Hauptthemen laut MEDLINE: Lafora Disease, Dependovirus, Genetic Therapy, Ubiquitin-Protein Ligases. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Spanish Ministry of Economy, Tatiana Perez de Guzman el Bueno Foundation, Fondazione Malattie Rare Mauro Baschirotto BIRD Onlus.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lafora disease is a fatal neurodegenerative disorder caused by loss-of-function mutations in the EPM2A or EPM2B genes, which encode laforin and malin, respectively. These mutations lead to the accumulation of intracellular inclusions of abnormal glycogen, known as Lafora bodies, the hallmark of the disease. Symptoms typically begin in early adolescence with seizures and rapidly progress to cognitive and motor decline, ultimately resulting in dementia and death within a decade of onset. Disruption of Epm2a or Epm2b in mice causes neuronal degeneration and Lafora body accumulation in the brain and other tissues. Epm2a−/− and Epm2b−/− mice exhibit motor and memory impairments, epileptic activity, and molecular and histological abnormalities. We previously demonstrated that intracerebroventricular delivery of a recombinant adeno-associated virus carrying EPM2A significantly improved pathology in Epm2a−/− mice. In this study, we tested recombinant adeno-associated virus-mediated delivery of the human EPM2B gene in Epm2b−/− mice. The treatment partially improved neurological, molecular, and histopathological outcomes, although some pathological features persisted. Importantly, our findings reveal differences between EPM2A- and EPM2B-based gene therapies, highlighting the need to better understand their distinct mechanisms. Despite limitations, our study provides new insights into the complexity of targeting EPM2B mutations in Lafora disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lafora DiseaseDependovirusGenetic TherapyUbiquitin-Protein LigasesProtein Tyrosine Phosphatases, Non-ReceptorAnimalsMiceMice, KnockoutHumansDisease Models, AnimalGenetic VectorsBrain

Stichwörter der Autor:innen

Epm2b−/− mouseLafora diseasegene therapymalinprogressive myoclonic epilepsyrAAV

Substanzen

Ubiquitin-Protein LigasesEpm2a protein, mouseProtein Tyrosine Phosphatases, Non-ReceptorNHLRC1 protein, mouse

Autor:innen und Institutionen

  • Laboratory of Neurology, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, Spain.
  • Fondazione Malattie Rare Mauro Baschirotto BIRD Onlus, 36023 Longare, VI, Italy.
  • Instituto de Biomedicina de Valencia, CSIC, Jaime Roig 11, 46010 Valencia, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 46010 Valencia, Spain.
  • Department of Biotechnology, Escuela Técnica Superior de Ingeniería Agronómica y del Medio Natural, Universitat Politécnica de València, 46022 Valencia, Spain.

ORCID-Profile: Luis Zafra-Puerta, Nerea Iglesias-Cabeza, Pascual Sanz, María Adelaida García-Gimeno, Marina P Sánchez

Förderung

  • Spanish Ministry of Economy
  • Tatiana Perez de Guzman el Bueno Foundation
  • Fondazione Malattie Rare Mauro Baschirotto BIRD Onlus
  • AEVEL Foundation
  • Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER)
  • National Institute of Neurological Disorders and Stroke of the National Institutes of Health

Zitieren

APA

Zafra-Puerta, L., Iglesias-Cabeza, N., Sanz, P., García-Gimeno, M. A., Sánchez-Martín, G., Sánchez, M. P., & Serratosa, J. M. (2025). Adeno-Associated Virus-Based Gene Therapy for Lafora Disease in Epm2b-Deficient Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262411930

Vancouver

Zafra-Puerta L, Iglesias-Cabeza N, Sanz P, García-Gimeno MA, Sánchez-Martín G, Sánchez MP, et al. Adeno-Associated Virus-Based Gene Therapy for Lafora Disease in Epm2b-Deficient Mice. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262411930

BibTeX
@article{ZafraPuerta2025,
  author = {Zafra-Puerta, Luis and Iglesias-Cabeza, Nerea and Sanz, Pascual and García-Gimeno, María Adelaida and Sánchez-Martín, Gema and Sánchez, Marina P and Serratosa, José M},
  title = {Adeno-Associated Virus-Based Gene Therapy for Lafora Disease in Epm2b-Deficient Mice},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262411930}
}
Kostenlos starten →